No Data
No Data
Shenyang Xingqi Pharmaceutical (300573.SZ): Currently, the company has no new coronavirus prevention and treatment drugs.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform on August 12th that the company currently has no COVID-19 prevention and treatment drugs.
Shenyang Xingqi Pharmaceutical (300573.SZ): In 2023, the company was awarded the title of "Provincial Green Factory" and passed the evaluation and acceptance of "Zero Waste Factory".
On August 9th, Gelon Hui Corporation reported on its investor interaction platform that Shenyang Xingqi Pharmaceutical actively practices a green low-carbon strategy, introduces innovative technologies to improve its green operation level, and reduces the impact of its business operations on the environment. In 2023, the company won the title of "Provincial Green Factory" and passed the "Zero Waste Factory" appraisal and acceptance. The company fully implements the relevant regulations of the green factory, focuses on building a green supply chain, realizes the full chain digital transformation from R&D to packaging, and continuously accelerates the pace of green and low-carbon transformation, jointly promoting the industry's green and high-quality development. In the future, the company will continue to practice the ESG development concept and promote
With A 25% Price Drop For Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) You'll Still Get What You Pay For
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-22031 eye drops obtained the notice of clinical trial approval.
On July 25th, Gelonghui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) has recently received a drug clinical trial approval notice for SQ-22031 eye drops issued by the National Medical Products Administration. SQ-22031 eye drops are category 1 biological products developed by our company for treatment. In clinical trials, it is intended to be used for (1) dry eye syndrome; (2) neurotrophic keratitis. Among them, indication (2) neurotrophic keratitis was included in the second batch of rare disease catalog in China in 2023. According to the relevant requirements for category 1 biological products for therapeutic use in the registration classification of biological products, the company has completed SQ-2.
No Data